Aratana Therapeutics, Inc. (PETX) Financial Statements (2024 and earlier)

Company Profile

Business Address 11400 TOMAHAWK CREEK PARKWAY, SUITE 340
LEAWOOD, KS 66211
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2019
MRQ
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 42,67167,61588,30386,20298,07245,754
Cash and cash equivalents 41,43166,86887,30726,7559,82341,084
Short-term investments 1,24074799659,44788,2494,670
Receivables 2,2042,4068760352 
Inventory, net of allowances, customer advances and progress billings 11,42513,57611,1301,30642755
Inventory 11,42513,57611,1301,30642755
Deferred costs  7620189  
Other undisclosed current assets 1,8271,5662,0021,2621,0582,656
Total current assets: 58,12785,239101,54289,01999,90948,465
Noncurrent Assets
Property, plant and equipment 6931,1661,9482,55562098
Long-term investments and receivables     2,452 
Long-term investments     2,452 
Intangible assets, net (including goodwill) 46,94547,91147,02154,848103,72166,936
Goodwill 40,84641,29539,38239,78141,39820,796
Intangible assets, net (excluding goodwill) 6,0996,6167,63915,06762,32346,140
Restricted cash and investments 351350350350  
Other noncurrent assets 3205265452941,20137
Total noncurrent assets: 48,30949,95349,86458,047107,99467,071
TOTAL ASSETS: 106,436135,192151,406147,066207,903115,536
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 5,41211,16313,2635,6476,8195,819
Interest and dividends payable     41 
Employee-related liabilities 2,587   2,0171,017
Accounts payable 9117,4517,4361,4001,5322,307
Accrued liabilities 1,9143,7125,8274,2473,2292,495
Debt  17,33314,413  8,625
Business combination, contingent consideration, liability     4,248
Deferred revenue and credits    800
Deferred tax liabilities     413 
Other liabilities   12374657
Other undisclosed current liabilities 1457,0007,000 (2,058)1,600
Total current liabilities: 5,55735,49634,6885,6849,46816,901
Noncurrent Liabilities
Long-term debt and lease obligation  19,49225,77539,71014,9639,310
Long-term debt, excluding current maturities  19,49225,77539,71014,9639,310
Liabilities, other than long-term debt 57705401221,6401,741
Deferred tax liabilities, net     1,6101,666
Other liabilities 57705401223075
Other undisclosed noncurrent liabilities      1,543
Total noncurrent liabilities: 5719,56226,31539,83216,60312,594
Total liabilities: 5,61455,05861,00345,51626,07129,495
Equity
Equity, attributable to parent, including: 100,82280,13490,403101,550181,83286,041
Common stock 484337353423
Treasury stock, value (1,175)(1,107)(1,088)(1,088)(1,081) 
Additional paid in capital 350,745321,599286,909263,941254,993112,515
Accumulated other comprehensive loss (7,558)(7,085)(9,862)(9,320)(4,150) 
Accumulated deficit (241,238)(233,316)(185,593)(152,018)(67,964) 
Other undisclosed equity, attributable to parent      (26,497)
Total equity: 100,82280,13490,403101,550181,83286,041
TOTAL LIABILITIES AND EQUITY: 106,436135,192151,406147,066207,903115,536

Income Statement (P&L) ($ in thousands)

3/31/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues 35,41225,57338,551678767123
Revenue, net25,57338,551678767123
Cost of revenue (7,800)(16,737)(3,518)(1,909)(2,337)(108)
Cost of goods and services sold (6,783)(16,387)(3,139)(365)(333)(108)
Gross profit: 27,6128,83635,033(1,231)(1,570)15
Operating expenses (39,500)(53,292)(65,852)(88,265)(40,039)(19,926)
Other undisclosed operating income      48
Operating loss: (11,888)(44,456)(30,819)(89,496)(41,609)(19,863)
Nonoperating income (expense) (2,834)(3,054)(2,756)3,7441,350121
Other nonoperating income (expense) (109)(22)2555,1402,287 
Interest and debt expense (3,391)(3,481)(3,396)(1,585)(1,060)(432)
Other undisclosed income from continuing operations before equity method investments, income taxes 3,3913,4813,3961,5851,060 
Loss from continuing operations before equity method investments, income taxes: (14,722)(47,510)(33,575)(85,752)(40,259)(20,174)
Other undisclosed income from continuing operations before income taxes      432
Loss from continuing operations before income taxes: (14,722)(47,510)(33,575)(85,752)(40,259)(19,742)
Income tax benefit    1,6981,44315,455
Loss from continuing operations: (14,722)(47,510)(33,575)(84,054)(38,816)(4,287)
Loss before gain (loss) on sale of properties: (14,722)(47,510)(33,575)(84,054)(38,816)(4,287)
Net loss available to common stockholders, diluted: (14,722)(47,510)(33,575)(84,054)(38,816)(4,287)

Comprehensive Income ($ in thousands)

3/31/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss: (14,722)(47,510)(33,575)(84,054)(38,816)(4,287)
Other comprehensive income (loss) (473)2,777(542)(5,170)(4,150) 
Comprehensive loss, net of tax, attributable to parent: (15,195)(44,733)(34,117)(89,224)(42,966)(4,287)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: